Maureen O'Brien
COG Phase I Consortium · Children's Hospital Medical Center, Cincinnati
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Maureen O'Brien as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:36 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02791919 · Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid LeukemiaNational Cancer Institute (NCI) · withdrawn · CNS 2a, CNS 2b, CNS 2c · principal investigator
- Ph1NCT02141828 · A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL GeneEpizyme, Inc. · completed · Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia · principal investigator
- Early Ph1NCT01658007 · Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/LymphomaChildren's Hospital Medical Center, Cincinnati · terminated · Relapsed Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Refractory Acute Lymphoblastic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pediatric Phase 1/Pilot ConsortiumUM1CA097452 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI Brenda J. Weigel · fiscal years 2009 to 2018Named on NCT02791919
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-11 23:36 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- 386 citationsRCR 9.7
- 94 citationsRCR 2.3
- Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.Pediatr Blood Cancer · 201027 citationsRCR 0.9
- Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study.Haematologica · 201424 citationsRCR 0.8
- Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.Pediatr Blood Cancer · 20258 citationsRCR 1.6
- Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia.Pediatr Blood Cancer · 20214 citationsRCR 0.2